Pointers in evidence-based guidelines on the request, execution, the reference of biochemical markers for cancer (tumor markers, biological markers);Appunti per linee guida evidence-based per la richiesta, l'esecuzione, la refertazione degli indicatori biochimici di cancro (marcatori tumorali, biomarcatori)

Rivista di Medicina di Laboratorio

Volumn 5, Issue 3, 2004, Pages 219-224

  Dorizzi, Romolo M ^a,b   Giavarina, D ^a   Fosser, V ^a   Fortunato, A ^a   Soffiati, G ^a   Rizzotti, P ^a  

^a Azienda Ospedaliera di Verona ^*

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

BIOCHEMISTRY; CANCER; CANCER DIAGNOSIS; CODING; CONTINUING EDUCATION; DECISION MAKING; DISEASE CLASSIFICATION; EVIDENCE BASED MEDICINE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LABORATORY TEST; PEER REVIEW; PRACTICE GUIDELINE; REVIEW;

EID: 4344693107     PISSN: 15923479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Sturgeon C. Practice Guidelines for Tumor Marker. Use in the Clinic. Clin Chem 2002; 48: 1151-8
2. American Society of Clinical Oncology: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996; 14:2843-77
3. Bast RC Jr, Radvin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1865-78.
4. Sturgeon C. Tumor Markers in the laboratory: closing the guideline-practice gap. Clin Biochem 2001; 34: 353-9.
5. Fleisher M, Dnistrian AM, Sturgeon CM, Lamerz R, Wittliff JL.Practice guidelines and recommendations for use of tumor markers in the clinic. In: Diamandis EP, Fritsche H, Schwartz MK, Chan DW, eds. Tumor markers: physiology, pathobiology, technology and clinical applications. Chicago: AACC Press, 2002:33-63
6. European Group for Tumor Markers (EGTM). Consensus recommendations. Anticancer Res 1999;19:2785-820.
7. Bormer OP. Tumor markers in an evidence-based medicine. Scand J Clin Lab Invest 2001; 61:317-20.
8. Duffy MJ. Clinical Uses of Tumor markers. Crit Rev Clin Lab Sci 2001; 38: 225-62.
9. Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum Tumor markers. Am Fam Physician 2003; 68: 1075-82.
10. Gion M. Guida all'uso clinico dei biomarcatory in Oncologia 2002. Milano: Biomeda 2002
11. Van Hingen HE, Chan DW, Hubl W, Miyachi H, Molin R, Pitzel L, et al. Analytical and clinical evaluation of an electrochemiluminescence immunoassay for the determination of CA 125. Clin Chem 1998; 44: 2530-6.
12. Bonfrer JMG, Korsel CM, Verstraeten RA, van Kamp GJ, Hart GAM, Kenemans P. Clinical evaluation of the Byk LIA-mat CA125 II assay: discussion of a reference value. Clin Chem 1997;43:491-497.
13. Steinberg W. The clinical utility of the CA 19-9 Tumor-associated antigen. Am J Gastroenterol 1990; 85: 350-5.
14. Lamerz R. CA15-3. In: Thomas L (Ed) Clinical Laboratory Diagnostics. Frankfurt: TH-Books 1998.
15. Eskelinen M, Tikanoja S, Collan Y. Use of tumor markers CA 15-3, MCA and CEA in breast cancer diagnostics. J Tumor Marker Oncology 1989;4: 39-44.
16. Molina R, Filella X, Mengual P, Prats M, Zanon G, Daniels M et al. MCA in patients with breast cancer: correlation with CEA and CA 15-3. Int J Biol Markers 1990;5: 14-21.
17. Molina R, Jo J, Filella X, Zanon G, Grau JJ, Joseph J et al. Mucin-like carcinoma associated antigen (MCA) in tissue and serum of patients with breast cancer: clinical applications in prognosis and disease monitoring. Int J Biol Markers 1993;8: 113-23.
18. Seregni E, Crippa F, Botti C, Bellotti MG, Bogni A, et al. Mucin-like carcinoma associated antigen (MCA) in breast cancer: clinical experience at the National Cancer Institute of Milan. Int J Biol Markers 1993;8: 124-9.
19. Lamerz R. AFP. In: Thomas L (Ed) Clinical Laboratory Diagnostics. Frankfurt: TH-Books 1998.
20. Wagener C. CEA. In: Thomas L (Ed) Clinical Laboratory Diagnostics. Frankfurt: TH-Books 1998.
21. Morell AR: CEA levels in non neoplastic disease. Int J Biol Markers 1992; 7: 160-6.
22. Gion M, Rampazzo A, Mione R, Bruscagnin G. Cost/effectiveness of carcinoembryonic antigen-importance of adequacy of routine requests of tumor markers malignancies. Int J Biol Markers 1992; 7: 179-82.
23. Lopez JB, Royan GP, Lakhwani MN, Mahadaven M, Timor J. CA 72-4 compared with CEA and CA 19-9 as a marker of some gastrointestinal malignancies. Int J Biol Markers 1999; 14: 172-7.
24. Mann K, Hormann R. HCG in Thomas L (Ed) Clinical Laboratory Diagnostics. Frankfurt: TH-Books 1998.
25. Lamerz R. NSE. In Thomas L (Ed) Clinical Laboratory Diagnostics. Frankfurt: TH-Books 1998.
26. Lamerz R. TAG 72-4 in Thomas L (Ed) Clinical Laboratory Diagnostics. Frankfurt: TH-Books 1998.
27. Schwartz MK. Biochemical markers in staging clinically organ confined prostate cancer. Molecular oncology 1997; 1: 129-32.
28. Steeber P, Dienemann H, Hasholzner U, Muller C, Poley S, Hofmann et al. Eur J Clin Chem Clin Biochem 1993; 31: 689-94.
29. Pannall P, Kotasek D. Cancer and Clinical Biochemistry. London: ACB 1997.
30. Tumor Marker Expert Panel (ASCO). Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996; 14: 2843-77.
31. Witliff JL, Kaplan LA (eds). Guidelines for the analytical performance and clinical utility of tumor markers. NACB: Rye Brook, NY 1998.
32. Wu J, Nakamura R. Human circulating tumor markers. Chicago: ASCP 1997.
33. 42 CFR Part 410 Medicare Program; Negotiated Rulemaking: Coverage and Administrative Policies for Clinical Diagnostic Laboratory Services; Final Rule. Federal Register / Vol. 66, No. 226 / Friday, November 23, 2001 / Rules and Regulations
34. McGinley PJ, Kilpatrick ES. Tumour markers: their use and misure by clinicians. Ann Clin Biochem 2003; 40: 643-7.
35. Smellie WSA. Appropriateness of test use in pathology: a new era or reinventing the wheel? Ann Clin Biochem 2003; 40:585-92.